Effective treatment of CLIPPERS with long-term use of rituximab
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received December 6, 2017
- Accepted in final form January 17, 2018
- First Published March 1, 2018.
Author Disclosures
- Veronica P. Cipriani, MD,
- Nancy Arndt, RN, MSCN,
- Peter Pytel, MD,
- Anthony T. Reder, MD and
- Adil Javed, MD, PhD
- Veronica P. Cipriani, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
National MS Society
NONE
NONE
NONE
NONE
NONE
NONE
- Nancy Arndt, RN, MSCN,
1.)Genzyme 3.)Bayer
NONE
1.)Genzyme 2.)Teva
NONE
NONE
NONE
NONE
NONE
1.)Genzyme 2.)Teva
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Peter Pytel, MD,
NONE
NONE
NONE
Editorial board of Modern Pathology
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NIA funding as co-investigator for unrelated studies on myopathies.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Acted as expert witness for an law firm
- Anthony T. Reder, MD and
(1) Abbott, ImmunoScience, Inc., (2) Questcor/Malinkrodt, (3) AstraZeneca, (4)Merck Serono, (5) Athena Diagnostics, Inc., (6) Sanofi-Aventis, (7) Bayer, (8) Biogen Idec, (9) BioMS Medical, (10) Blue Cross Blue Shield, (11) Boehringer Ingelheim, (12) Caremark Rx, (13) Centocor Ortho Biotech Inc., (14) Cephalon, Inc., (15) Connetics Corp., (16) CroMedica Global Inc., (17) Eli Lilly and Company, (18) Elan Corporation, (19) Genentech, Inc., (20) Genzyme Corporation, (21) GlaxoSmithKline, (22) Hoechst Marion Roussel Canada Research, Inc., (23) Roche, (24) Immunex Corporation, (25) Institute for Health Care Quality, (26) Johnson & Johnson, (27) Yale University, (28) Barrow Neurological Institute, (29) National Multiple Sclerosis Society & Paralyzed Veterans of America, (30) Neurocrine Biosciences, (31) Novartis, (32) Parke-Davis, (33) Pfizer Inc., (34) Pharmacia & Upjohn, (35) Protein Design Labs, Inc., (36) Quantum Biotechnologies, Inc., (37) Quintiles, Inc., (38) EMD Serono, Inc., (39 Sention, Inc., (40) Smith Kline- Beecham, (41) Specialized Therapeutics (a division of Berlipharm, Inc.), (42) Takeda Pharmaceutical Company Limited, (43) Teva Pharmaceutical Industries Ltd.
NONE
(1) Abbott, ImmunoScience, Inc., (2) Questcor/Malinkrodt, (3) AstraZeneca, (4)Merck Serono, (5) Athena Diagnostics, Inc., (6) Sanofi-Aventis, (7) Bayer Schering Pharma, (8) Biogen Idec, (9) BioMS Medical, (10) Blue Cross Blue Shield, (11) Boehringer Ingelheim, (12) Caremark Rx, (13) Centocor Ortho Biotech Inc., (14) Cephalon, Inc., (15) Connetics Corp., (16) CroMedica Global Inc., (17) Eli Lilly and Company, (18) Elan Corporation, (19) Genentech, Inc., (20) Genzyme Corporation, (21) GlaxoSmithKline, (22) Hoechst Marion Roussel Canada Research, Inc., (23) Roche, (24) Immunex Corporation, (25) Institute for Health Care Quality, (26) Johnson & Johnson, (27) Yale University, (28) Barrow Neurological Institute, (29) National Multiple Sclerosis Society & Paralyzed Veterans of America, (30) Neurocrine Biosciences, (31) Novartis, (32) Parke-Davis, (33) Pfizer Inc., (34) Pharmacia & Upjohn, (35) Protein Design Labs, Inc., (36) Quantum Biotechnologies, Inc., (37) Quintiles, Inc., (38) EMD Serono, Inc., (39 Sention, Inc., (40) Smith Kline- Beecham, (41) Specialized Therapeutics (a division of Berlipharm, Inc.), (42) Takeda Pharmaceutical Company Limited, (43) Teva Pharmaceutical Industries Ltd.
(1) Medlink/Neurobase Editorial Board, Arbor Publishing Corporation, San Diego, CA, 1999-Present; (2) Turkish Journal of Medical Sciences, Editorial Board, 2001- present; (3) T?rk N?roloji Dergisi (Turkish Journal of Neurology), Editorial Board, 2004-present
NONE
NONE
NONE
(1) Abbott, (2) Questcor/Malinkrodt,(3) AstraZeneca, (4) Merck Serono, (5) Athena Diagnostics, Inc., (6) Sanofi- Aventis, (7) Bayer Schering Pharma, (8) Biogen Idec, (9) BioMS Medical, (10) Blue Cross Blue Shield, (11) Boehringer Ingelheim, (12) Caremark Rx, (13) Centocor Ortho Biotech Inc., (14) Cephalon, Inc., (15) Connetics Corp., (16) CroMedica Global Inc., (17) Eli Lilly and Company, (18) Elan Corporation, (19) Genentech, Inc., (20) Genzyme Corporation, (21) GlaxoSmithKline, (22) Hoechst Marion Roussel Canada Research, Inc., (23) Roche, (24) Immunex Corporation, (25) Institute for Health Care Quality, (26) Johnson & Johnson, (27) Yale University, (28) Barrow Neurological Institute, (29) National Multiple Sclerosis Society & Paralyzed Veterans of America, (30) Neurocrine Biosciences, (31) Novartis, (32) Parke-Davis, (33) Pfizer Inc., (34) Pharmacia & Upjohn, (35) Protein Design Labs, Inc., (36) Quantum Biotechnologies, Inc., (37) Quintiles, Inc., (38) EMD Serono, Inc., (39 Sention, Inc., (40) Smith Kline- Beecham, (41) Specialized Therapeutics (a division of Berlipharm, Inc.), (42) Takeda Pharmaceutical Company Limited, (43) Teva Pharmaceutical Industries Ltd.
NONE
NONE
NONE
(1) Novartis, (2) Bayer, (3) Serono, Inc., (4) Chugai, (5) Genzyme,(6) Biogen Idec, (7)Medimmune (8) Genentech/Roche, Inc., (8) Medday
(1) NIH/NINDS RO1 NS 051591, Site PI; (2) NIH 1 K24 RR021948, PI. (2) Chinese Government, (3) Turkish Ministry of Defense Fellowship Award, (4) the State of Illinois
NONE
(1) the National MS Society, (2) the Brain Research Foundation, (3) the American Academy of Allergy & Immunology, (4) Howard Hughes Foundation, (5) Egypt Arab Republic Peace Fellowship,
NONE
NONE
NONE
NONE
NONE
NONE
- Adil Javed, MD, PhD
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Dr. Javed has been a consultant for Biogen, Sanofi- Genzyme, Serono, Mallinckrodt, and Genentech.
Dr. Javed serves on the speaker's bureau for Biogen, Sanofi-Genzyme, Serono, Teva, Mallinckrodt, and Genentech.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the Department of Neurology (V.P.C., N.A., A.T.R., A.J.), and Department of Pathology (P.P.), University of Chicago, IL.
- Correspondence
Dr. Cipriani vpenyak{at}gmail.com
Article usage
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg
► Watch
Related Articles
- No related articles found.
Topics Discussed
Alert Me
Recommended articles
-
Article
Widespread inflammation in CLIPPERS syndrome indicated by autopsy and ultra-high-field 7T MRIMorten Blaabjerg, Klemens Ruprecht, Tim Sinnecker et al.Neurology - Neuroimmunology Neuroinflammation, April 20, 2016 -
Article
Hemophagocytic Lymphohistiocytosis Gene Mutations in Adult Patients Presenting With CLIPPERS-Like SyndromeGuillaume Taieb, Elsa Kaphan, Claire Duflos et al.Neurology: Neuroimmunology & Neuroinflammation, March 03, 2021 -
Clinical/Scientific Notes
Expanding the MOG phenotypeBrainstem encephalitis with punctate and curvilinear enhancementSusan Matesanz, Chelsea Kotch, Christopher Perrone et al.Neurology: Neuroimmunology & Neuroinflammation, September 13, 2019 -
Clinical/Scientific Notes
A case of CLIPPERS syndrome responsive to tocilizumabTorge Rempe, Jos Steffen Becktepe, Imke Metz et al.Neurology: Neuroimmunology & Neuroinflammation, February 04, 2019